Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's HS-001?
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's HS-001?
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure. According...